In this trial researchers, including Western Health's Director of Intensive Care
Services, A/Prof Craig French, studied the effect Erythropoietin might have on
neurological recovery, mortality and venous thrombotic events in patients with
traumatic brain injury. The research has been published in the prestigious
medical journal, The Lancet.
Erythropoietin in Traumatic Brain Injury (EPO-TBI) was a double-blind,
placebo-controlled trial undertaken in 29 centres (all university-affiliated
teaching hospitals) in seven countries (Australia, New Zealand, France, Germany,
Finland, Ireland, and Saudi Arabia).
To read more about this trial, please click on the following link to the Erythropoietin
in traumatic brain injury (EPO-TBI): a double‑blind randomised controlled
trial.
A/Prof French also presented the findings in Berlin in the Hot Topics session
of the European Society of Intensive Care Medicine Meeting. Please click on the
following link to view the presentation.
